FLUDITEC

This brand name is authorized in Nigeria. It is also authorized in Estonia, Lithuania.

Active ingredients

The drug FLUDITEC contains one active pharmaceutical ingredient (API):

1	Carbocisteine UNII 740J2QX53R - CARBOCYSTEINE
	Carbocisteine (5-carboxymethyl L-cysteine) has been shown in normal and bronchitic animal models to affect the nature and amount of mucus glycoprotein that is secreted by the respiratory tract. An increase in the acid:neutral glycoprotein ratio of the mucus and a transformation of serous cells to mucus cells is known to be the initial response to irritation and will normally be followed by hypersecretion.
	Read more about Carbocisteine

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-3446	Syrup	Fluditec 5% SYRUP 5%	Each 5 mL Syrup contains: Carbocisteine 250 mg	19/02/2021
B4-5477	Syrup	Fluditec 2% SYRUP 2%	Each 5 mL Syrup contains: Carbocisteine 100 mg	19/02/2021

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R05CB03	Carbocisteine	R Respiratory system → R05 Cough and cold preparations → R05C Expectorants, excl. combinations with cough suppressants → R05CB Mucolytics
Discover more medicines within R05CB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1022522, 1022533
LT	Valstybinė vaistų kontrolės tarnyba	1015944, 1015948
NG	Registered Drug Product Database	B4-3446, B4-5477